Goodnow R.A.,40 Kingsland Street |
Hicks A.,40 Kingsland Street |
Sidduri A.,40 Kingsland Street |
Kowalczyk A.,40 Kingsland Street |
And 38 more authors.
Journal of Medicinal Chemistry | Year: 2010
The inhibition of LTB4 binding to and activation of G-protein-coupled receptors BLT1 and BLT2 is the premise of a treatment for several inflammatory diseases. In a lead optimization effort starting with the leukotriene B4 (LTB4) receptor antagonist (2), members of a series of 3,5-diarylphenyl ethers were found to be highly potent inhibitors of LTB4 binding to BLT1 and BLT2 receptors, with varying levels of selectivity depending on the substitution. In addition, compounds 33 and 38 from this series have good in vitro ADME properties, good oral bioavailability, and efficacy after oral delivery in guinea pig LTB4 and nonhuman primate allergen challenge models. Further profiling in a rat non-GLP toxicity experiment provided the rationale for differentiation and selection of one compound (33) for clinical development. © 2010 American Chemical Society.